- Home
- STOK vs VINP Comparison
STOK vs VINP Comparison
Compare STOK & VINP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STOK
- VINP
- Stock Information
- Founded
- STOK 2014
- VINP 2009
- Country
- STOK United States
- VINP Brazil
- Employees
- STOK N/A
- VINP N/A
- Industry
- STOK Biotechnology: Pharmaceutical Preparations
- VINP Investment Managers
- Sector
- STOK Health Care
- VINP Finance
- Exchange
- STOK Nasdaq
- VINP Nasdaq
- Market Cap
- STOK 517.0M
- VINP 616.8M
- IPO Year
- STOK 2019
- VINP 2021
- Fundamental
- Price
- STOK $9.36
- VINP $10.09
- Analyst Decision
- STOK Strong Buy
- VINP Strong Buy
- Analyst Count
- STOK 5
- VINP 2
- Target Price
- STOK $27.50
- VINP $13.25
- AVG Volume (30 Days)
- STOK 813.9K
- VINP 61.5K
- Earning Date
- STOK 05-20-2025
- VINP 05-12-2025
- Dividend Yield
- STOK N/A
- VINP 6.44%
- EPS Growth
- STOK N/A
- VINP N/A
- EPS
- STOK N/A
- VINP 0.34
- Revenue
- STOK $36,555,000.00
- VINP $97,136,413.00
- Revenue This Year
- STOK $27.80
- VINP $27.12
- Revenue Next Year
- STOK $9.53
- VINP $16.70
- P/E Ratio
- STOK N/A
- VINP $30.00
- Revenue Growth
- STOK 316.34
- VINP 32.21
- 52 Week Low
- STOK $5.35
- VINP $8.66
- 52 Week High
- STOK $17.58
- VINP $11.62
- Technical
- Relative Strength Index (RSI)
- STOK 57.94
- VINP 61.88
- Support Level
- STOK $8.30
- VINP $9.56
- Resistance Level
- STOK $10.12
- VINP $9.89
- Average True Range (ATR)
- STOK 0.59
- VINP 0.28
- MACD
- STOK -0.03
- VINP 0.07
- Stochastic Oscillator
- STOK 58.24
- VINP 96.15
About STOK Stoke Therapeutics Inc.
Stoke Therapeutics Inc is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine. Its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach, Stoke is developing antisense oligonucleotides (ASOs) to restore naturally-occurring protein levels selectively. Its first medicine in development, zorevunersen, has demonstrated the potential for disease modification in patients with Dravet syndrome. The company provides early programs focused on multiple targets, including haploinsufficiency diseases of the central nervous system and eye, to up-regulate the protein expression of the underlying disease gene in a mutation-agnostic manner.
About VINP Vinci Partners Investments Ltd.
Vinci Partners Investments Ltd is an alternative investment platform in Brazil. Its business segments include Private Market; Liquid Strategies; Investment Products and solutions; Financial Advisory; and Retirement Services. The company's majority of its revenue comes from the Private Market segment which is comprised of five business lines: private equity, real estate, infrastructure, credit, and special situations.